US EditionWhy Eli Lilly Stock Flopped on Friday
5 Articles
5 Articles
Why Eli Lilly Stock Flopped on Friday
Key PointsFoundayo's initial prescription count was notably lower than that of its rival.This is Eli Lilly's first FDA-approved weight-loss pill.10 stocks we like better than Eli Lilly › Doubts about a high-profile new product dampened investor enthusiasm for Eli Lilly (NYSE: LLY) stock on Friday. The giant pharmaceutical company didn't have a good trading session, with sell-offs driving its price down by almost 4% over the course of the day. To…
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start
Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6. The post Eli Lilly’s New Weight-Loss Pill Has an Early Problem: N…
New data: Novo beats Eli Lilly's pill sales in the USANovo rival Eli Lilly's weight loss pill, Foundayo, which was approved for sale in the US by the US Food and Drug Administration (FDA) at the beginning of the month, has few
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
